# Longbow Capital

> Longbow Capital is a VC fund in Norwich backing Biotechnology and Health Care. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Norwich, United Kingdom
- Total investments: 12
- Last investment: Apr 2021
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/longbow-capital-llp
- Website: http://www.longbow.co.uk

Longbow Capital is an investment management firm focused on the healthcare, well-being, and life sciences sectors.The firm offer tax-efficient investing into cutting edge, innovative companies with the potential for high returns. It also provides capital, connections, and experience; in particular for consumer health product businesses.DouglasSnyder, Edward Beckett, and Ron Petersen in 2004, with its general headquarters in Norwich, Norfolk.

## Contacts

5 contacts available for Longbow Capital. Shizune tracks 6 team members at Longbow Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/longbow-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 50% |
| Health Care | 4 | 33% |
| Medical | 3 | 25% |
| Software | 2 | 17% |
| Cloud Computing | 2 | 17% |

21 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Funding Round | 5 | 42% |
| Series A | 2 | 17% |
| Series C | 2 | 17% |
| Angel | 1 | 8% |
| Series B | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 7 | 58% |
| Canada | 1 | 8% |
| The Netherlands | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bill Husselby | Management Partner | 0 | — |
| Chris Outram | Management Partner | 0 | — |
| Colin Bothway | Management Partner | 0 | — |
| Edward Beckett | Co-founder and Managing Partner | 0 | — |
| Nick Lyons | Chairman | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Bird | MessageBird powers communication between businesses and their customers — across any channel, always with the right context, and on every corner of the planet. Its products and solutions are the foundational building blocks to business communications across preferred channels, like SMS, Voice, WhatsApp, WeChat, Messenger, Email and more. Founded inAmsterdam in 2011, MessageBird connects to billions of devices and is trusted by nearly 20,000 customers. It operates across nine worldwide hubs and is proud to be a “Work Anywhere” company. | $800M | Series C | Apr 28, 2021 |  |
| Galatea Technologies | Galatea Technologies creates a sophisticated platform to aggregate, analyze, and optimize a multitude of constantly changing logistics-focused, capacity-centric decision-making processes in a world full of use cases. Its first application, Waste Coordinator, is a SaaS product tailored to the oilfield waste vertical. Its automation technologyoptimizes oilfield transportation workflows digitally, allowing users to easily maximize operational, financial, and environmental performance. | $600K | Angel | Mar 21, 2021 |  |
| Bird | MessageBird powers communication between businesses and their customers — across any channel, always with the right context, and on every corner of the planet. Its products and solutions are the foundational building blocks to business communications across preferred channels, like SMS, Voice, WhatsApp, WeChat, Messenger, Email and more. Founded inAmsterdam in 2011, MessageBird connects to billions of devices and is trusted by nearly 20,000 customers. It operates across nine worldwide hubs and is proud to be a “Work Anywhere” company. | $200M | Series C | Oct 08, 2020 |  |
| Domainex | Domainex Ltd is a contract research company that was established in 2001 and operates from Cambridge UK. In May 2007 Domainex merged with NCE Discovery to form a new integrated company with capabilities in biology and chemistry. Service division offers technologies designed to clone and express challenging genes to give high-quality recombinantprotein displaying functional domains of the target. We also provide computational and medicinal chemistry for the design and synthesis of candidate drugs aimed at our customers' target proteins. | $2M | Series A | Feb 01, 2013 |  |
| Sky Medical Technology | Sky Medical Technology is a growth-stage bioelectronic medicine platform that completely redefines the way vascular related conditions are treated. The company has developed a neuromodulation therapy called OnPulse™, the first clinically proven bioelectronic compression technology to prevent and treat a wide range of acute and chronic circulatoryconditions. The first indications for the OnPulse wearable therapy are life threatening blood clots, swelling after orthopedic surgery, long term non-healing wounds, as well as applications for pro athletes to speed-up recovery time between games and during travel, conditions experienced by more than forty million people currently with unmet need. |  |  | Jan 01, 2013 |  |
| RepRegen | A spin-out from Imperial Innovations plc and headquartered within the Imperial College Incubator, RepRegen is poised to commercialize the initial product of its hard tissue repair and regeneration platform: StronBoneâ„¢ Bone Graft Substitute. The Company's hard tissue platform is based on 'smart' bioceramics designed to be used,initially, by orthopedic product manufacturers and surgeons. A major RepRegen materials science innovation is the use of Strontium, boosting the performance of the bioceramics. | $1.6M |  | Nov 16, 2010 |  |
| Ambicare Health | Ambicare Health Ltd developed a portfolio of wearable light sources for medical and consumer healthcare applications.The concept underpinning all of Ambicare’s technology has been to replicate the science of light therapies already clinically proven and practiced in central medical facilities, but to deliver them in a highly convenient form foruse in community medicine or home settings, through use of convenient, wearable LED treatment heads and a rechargeable treatment controller.Since its founding as the result of pioneering work done at the University of St. Andrews and Tayside Health Board (NHS) in 2004, Ambicare has made substantial progress in the development and commercialisation of proprietary, light emitting diode (LED) based devices for the treatment of a range of skin conditions and diseases. Ambicare has developed two distinct product lines, both of which are clinically proven and convenient to use, for the treatment of specific dermatological conditions: non-melanoma skin cancer and acne. | $2.6M |  | Jul 26, 2010 |  |
| PolyTherics | PolyTherics has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimisedclinical candidates. | $4M | Series C | Apr 15, 2010 |  |
| BioCeramic Therapeutics | BioCeramic Therapeutics Ltd. develops medical interventions that enable the body to renew damaged tissues. It offers products to help patients suffering from a range of bone and soft tissue related conditions. BioCeramic Therapeutics Ltd. was formerly known as Advanced Tissue Therapies Ltd. and changed its name to BioCeramic Therapeutics Ltd. in2007. The company was incorporated in 2006 and is based in London, the United Kingdom. | $1.9M | Series B | Jan 17, 2010 |  |
| Biotronics3D | Biotronics3D, headquartered in London, England, develops and markets innovative software applications for the diagnostic imaging industry. They provide cutting edge software technologies to improve healthcare by better extracting diagnostic data and transforming it into usable information available at the point-of-care. Biotronics3D Ltd is an ENISO 13485:2003 certified company. Their flagship product, 3Dnet Enterprise Suite, has received FDA 510K market clearance and it is CE marked. | $1.3M | Series A | Nov 14, 2008 |  |

10 of 12 investments shown.

## Co-investors
- [Imperial Innovations](https://shizune.co/investors/profile/imperial-innovations) — VC Fund, 4 deals together
- [Atomico](https://shizune.co/investors/profile/atomico) — VC Fund, 2 deals together
- [Bonnier Capital](https://shizune.co/investors/profile/bonnier-ventures) — VC Fund, 2 deals together
- [Glynn Capital Management](https://shizune.co/investors/profile/glynn-capital-management) — VC Fund, 2 deals together
- [Juno Capital Partners](https://shizune.co/investors/profile/juno-capital) — VC Fund, 2 deals together
- [Lightrock](https://shizune.co/investors/profile/lgt-lightstone) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Longbow Capital invest in?

Longbow Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series A stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Longbow Capital?

Public channels for Longbow Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Longbow Capital?

The team at Longbow Capital includes Bill Husselby (Management Partner), Chris Outram (Management Partner) and Colin Bothway (Management Partner), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co